• RG108 DNA Methyltransferase Inhibitor: Protocols & Innovatio

  2026-05-26

  RG108 empowers precise epigenetic modulation by selectively inhibiting DNA methyltransferases without covalent enzyme trapping, enabling researchers to reactivate silenced tumor suppressor genes and explore advanced cancer and stem cell applications. Uniquely, its non-nucleosidic mechanism and high solubility offer workflow flexibility, while recent in vivo studies illuminate both its utility and limitations for pluripotency induction.

• D2-like Dopamine Receptor Activation Restores Network Functi

  2026-05-26

  The reference study demonstrates that activation of D2-like dopamine receptors significantly alleviates neuronal network and cognitive deficits in a mouse model of infantile neuronal ceroid lipofuscinosis (INCL) caused by PPT1 deficiency. These findings highlight the therapeutic potential of targeting specific dopamine receptor subtypes to mitigate neurodegenerative pathology linked to disrupted protein palmitoylation.

• Frizzled5 Links Cholesterol Metabolism to Wnt/β-Catenin in C

  2026-05-25

  This study reveals that Frizzled5 (Fzd5) uniquely binds cholesterol through its extracellular linker, enabling receptor maturation and promoting Wnt/β-catenin signaling in pancreatic cancer. The findings establish Fzd5 as a cholesterol sensor and highlight a new mechanistic connection between lipid metabolism and oncogenic signaling, suggesting novel therapeutic opportunities.

• Tropisetron Hydrochloride (SKU B2258): Reliable 5-HT3 Antago

  2026-05-25

  This article delivers scenario-driven, evidence-based guidance for using Tropisetron Hydrochloride (SKU B2258) in cell viability and transporter assays. Drawing on validated data and peer-reviewed references, it addresses real-world laboratory challenges and demonstrates how SKU B2258 provides reproducible, high-purity solutions for serotonin receptor signaling research and neuroscience receptor modulation.

• Z-YVAD-FMK: Caspase-1 Inhibitor Workflows in Cell Death Rese

  2026-05-24

  Z-YVAD-FMK stands out as a selective, irreversible caspase-1 inhibitor, enabling high-fidelity apoptosis and pyroptosis studies. This article details stepwise protocols, troubleshooting strategies, and insights from recent landmark research to optimize inflammasome and cell death assays.

• CCK-8s Induces ANP Secretion via NOX4–PGC-1α–PPAR Signaling

  2026-05-23

  This study demonstrates that sulfated cholecystokinin octapeptide (CCK-8s) directly promotes atrial natriuretic peptide (ANP) secretion in isolated beating rat atria by activating the NOX4–PGC-1α–PPARα/PPARγ signaling axis. The findings provide mechanistic insight into cardiac hormone regulation, with implications for metabolic and cardiovascular research.

• Phenothiazines Boost Macrophage Antibacterial Activity via R

  2026-05-22

  This study demonstrates that phenothiazines, including perphenazine, enhance macrophage-mediated antibacterial responses by inducing reactive oxygen species (ROS) and autophagy. These findings advance host-directed therapy strategies against intracellular pathogens, offering a promising avenue for combating antibiotic resistance.

• Azilsartan Medoxomil Monopotassium: Precision in Hypertensio

  2026-05-22

  Azilsartan medoxomil monopotassium (TAK 491) stands out for its sustained, selective AT1 antagonism, empowering advanced blood pressure and cardiovascular disease models. This article delivers actionable workflows, troubleshooting guidance, and real-world protocol enhancements for maximizing research reproducibility with this potent ARB.

• Ziprasidone Augmentation in Escitalopram-Treated Anxious Dep

  2026-05-21

  This article examines a pivotal study investigating whether ziprasidone augmentation improves outcomes for patients with major depressive disorder (MDD) and high anxiety already receiving escitalopram. The findings refine expectations for combination therapy in antidepressant research, highlighting the nuanced effects on depressive and anxiety symptoms.

• Ribonuclease R (20 U/μL): Enabling Reliable Circular RNA Enr

  2026-05-21

  Ribonuclease R (RNase R) (20 U/μL) from APExBIO delivers robust and selective linear RNA degradation, transforming the accuracy of circular RNA enrichment in cancer and immunology research. This article walks through advanced, evidence-backed workflows, troubleshooting strategies, and data-driven protocol enhancements to empower reproducible circRNA analysis in complex biological systems.

• Gemcitabine HCl: Advanced Protocols for Pancreatic Tumor Mod

  2026-05-20

  Gemcitabine HCl enables high-precision pancreatic cancer research, especially when paired with innovative multianimal MRI workflows. This article decodes practical assay setups, troubleshooting, and evidence-backed enhancements for tumor growth suppression and apoptosis induction studies.

• EdU Flow Cytometry Assay Kits (Cy3): Streamlining S-Phase An

  2026-05-20

  The EdU Flow Cytometry Assay Kits (Cy3) empower researchers to achieve precise, denaturation-free DNA synthesis detection for high-content cell cycle and genotoxicity studies. By leveraging click chemistry, these kits outperform traditional BrdU assays, facilitating multiplexing and advanced pharmacodynamic evaluations.

• Dasatinib (BMS-354825): Precision Kinase Inhibition in EMT a

  2026-05-19

  Explore how Dasatinib (BMS-354825) advances kinase-driven malignancy research by dissecting its impact on EMT, cancer stemness, and protocol optimization. This in-depth guide delivers unique insights for translational scientists leveraging Dasatinib in diverse oncological models.

• Functionally Selective 5-HT1A Agonists for Non-Opioid Pain R

  2026-05-19

  The reference study reports the discovery of ST171, a novel, functionally selective serotonin 5-HT1A receptor agonist with potent antinociceptive effects and minimal sedative side effects. By leveraging high-content screening of FDA-approved drugs and structural analyses, the research highlights new avenues for developing safer, non-opioid analgesics.

• ATRX Loss Sensitizes Glioma to Selective PDGFR Inhibition

  2026-05-18

  This study demonstrates that ATRX-deficient high-grade glioma cells are particularly vulnerable to receptor tyrosine kinase (RTK) and PDGFR inhibitors. The findings highlight the importance of ATRX mutation status as a biomarker for targeted therapy and inform the design of future cancer research workflows.

454 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page